Subscribe to Newsletter

Increase viable CHO cell density in commercial available cell culture medium by supplementation with recombinant insulin

Please log in for more information

 

Read the full article now

Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!

Login
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

Company Information

Novo Nordisk Pharmatech A/S, Københavnsvej 216, 4600 Koege, Denmark
Tel: +45 5667 1000
Fax: +45 5667 1001
Email: [email protected]

Company website

Novo Nordisk Pharmatech A/S was established in 1949. It is the leading worldwide supplier of recombinant insulin, which is sourced directly from Novo Nordisk, the world’s largest producer. Its recombinant insulin is a key component in serum free growth media for mammalian cells and approved by regulatory bodies worldwide, including FDA and EMA. The company’s products are manufactured to cGMP standards, and have distinguished itself for:

- Global regulatory compliance
- Consistent high quality
- Extensive regulatory documentation
- Continuous availability
- Secure global supply chain
- High levels of service and support

More content by Novo Nordisk

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine

Register